



AVIZAT

Director CSUD.....

VERIFICAT ÎNDEPLINIRE STANDARDE I.O.S.U.D. - UMFCD

DA

NU

Director Școală doctorală.....

FIȘA DE VERIFICARE

a îndeplinirii standardelor I.O.S.U.D. Universitatea de Medicină și Farmacie “Carol Davila” București
în vederea obținerii atestatului de abilitare

Domeniile de doctorat: Medicină, Farmacie

I. Date despre candidat

Nume: ANUȚA

Prenume: VALENTINA

Gradul didactic/de cercetare: Conferențiar Dr.

Încadrat în prezent în învățământul superior:

DA NU

Disciplina Chimie-Fizică și Coloidală, Departamentul Farmacie I – Științe Fundamentale, Facultatea Farmacie, Universitatea de Medicină și Farmacie “Carol Davila” din București

Medic/Farmacist rezident/specialist/primar: Farmacist specialist

DA NU

Ordinul de confirmare: Ordin O.M.S nr.183/2015

II. Date privind îndeplinirea condițiilor de abilitare

Doctor în științe

DA NU

Titlul tezei de doctorat: „Particularități bioanalitice și farmacocinetice în evaluarea bioechivalenței medicamentelor cu metaboliți activi” (Ordin M.E.C.T. nr. 4387/06.06.2011); Coordonator: Prof. Dr. Constantin Mircioiu



Ordinul de confirmare:

III. Date numerice privind îndeplinirea standardelor minime naționale, conform anexelor nr. 20 și 23 ale Ordinului Ministrului Educației Naționale și Cercetării Științifice nr. 6129/20.12.2016

1. Articole publicate în reviste cotate ISI în calitate de autor principal

Criteriul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI în calitate de autor principal	10	33

Criteriu îndeplinit: DA NU

Lista articolelor ISI publicate în calitate de autor principal: autori, titlu articol, revistă, an, volum, pagini, factor de impact

1. Cocoș FI; Anuta V; Popa L; Ghica MV; Nica MA; Mihaila M; Fierascu RC; Trica B; Nicolae CA; Dinu-Pîrvu CE. Development and evaluation of docetaxel-loaded nanostructured lipid carriers for skin cancer therapy. *Pharmaceutics* 2024, 16, doi:10.3390/pharmaceutics16070960. (IF – 4.9/2023, Q1, autor corespondent) <https://www.mdpi.com/1999-4923/16/7/960>
2. Nica MA; Anuța V; Nicolae CA; Popa L; Ghica MV; Cocoș F-I; Dinu-Pîrvu C-E. Exploring deep eutectic solvents as pharmaceutical excipients: Enhancing the solubility of ibuprofen and mefenamic acid. *Pharmaceutics* 2024, 17, doi:10.3390/ph17101316 (IF – 4.3/2023, Q1, autor corespondent) <https://www.mdpi.com/1424-8247/17/10/1316>
3. Ozon EA; Mati E; Karampelas O; Anuta V; Sarbu I; Musuc AM; Mitran RA; Culita DC; Atkinson I; Anastasescu M; Lupuliasa D; Mitu MA. The development of an innovative method to improve the dissolution performance of rivaroxaban. *Heliyon* 2024, 10, doi:10.1016/j.heliyon.2024.e33162 (IF – 3.4/2023, Q1, autor corespondent) <https://www.cell.com/action/showPdf?pii=S2405-8440%2824%2909193-X>
4. Anuta V; Talianu MT; Dinu-Pirvu CE; Ghica MV; Prisada RM; Kaya MGA; Popa L. Molecular mapping of antifungal mechanisms accessing biomaterials and new agents to target oral candidiasis. *International Journal of Molecular Sciences* 2022, 23, doi:10.3390/ijms23147520 (IF -5.6/2022, Q1 – prim autor) <https://www.mdpi.com/1422-0067/23/14/7520>
5. Fita AC; Secareanu AA; Musuc AM; Ozon EA; Sarbu I; Atkinson I; Rusu A; Mati E; Anuta V; Pop AL. The influence of the polymer type on the quality of newly developed oral immediate-release tablets containing amiodarone solid dispersions obtained by hot-melt extrusion. *Molecules* 2022, 27, doi:10.3390/molecules27196600 (IF – 4.6/2022, Q2, autor corespondent) <https://www.mdpi.com/1420-3049/27/19/6600>
6. Shleghm MR; Mircioiu C; Voicu VA; Mircioiu I; Anuta V. Estimation of the in vivo release of amiodarone from the pharmacokinetics of its active metabolite and correlation with its in vitro release. *Frontiers in Pharmacology* 2021, 11: 621667, doi:10.3389/fphar.2020.621667 (IF – 5.988/2021, Q1 – ultim autor) <https://www.frontiersin.org/articles/10.3389/fphar.2020.621667/full>



7. **Anuta V**; Mircioiu C; Voicu V; Mircioiu I; Sandulovici R. Square root law model for the delivery and intestinal absorption of drugs: A case of hydrophilic captopril. *Drug Delivery*, 2021, 28(1), 1685-1694, doi:10.1080/10717544.2021.1960929 (IF -6.819/2021, Q1 – **prim autor**) <https://www.tandfonline.com/doi/full/10.1080/10717544.2021.1960929>
8. Musuc AM; **Anuta V**; Atkinson I; Sarbu I; Popa VT; Munteanu C; Mircioiu C; Ozon EA; Nitulescu GM; Mitu MA. Formulation of chewable tablets containing carbamazepine-beta-cyclodextrin inclusion complex and f-melt disintegration excipient. The mathematical modeling of the release kinetics of carbamazepine. *Pharmaceutics*, 2021, 13(6): 915, doi:10.3390/pharmaceutics13060915 (IF -6.525/2021, Q1 - **contribuție egală cu a primului autor**), <https://www.mdpi.com/1999-4923/13/6/915>
9. Sandulovici R; Mircioiu I; Aboul-Enein HY; Manolache M; Mircioiu C; Voicu V; **Anuta V**. Sources of outlier data in the bioanalytical and clinical part of a piroxicam bioequivalence study. *International Journal of Clinical Pharmacology and Therapeutics*, 2020, 58(11), 652-663, doi:10.5414/cp203794 (IF - 1.366/2020, Q4 – **ultimul autor**) https://www.dustri.com/article_response_page.html?artId=187231&doi=10.5414/CP203794&L=0
10. Hirjau M; Miron DS; **Anuta V**; Lupuliasa D; Ghica MV; Jinga V; Dinu-Pirvu CE. Evaluation of experimental multi-particulate polymer-coated drug delivery systems with meloxicam. *Coatings* 2020, 10(5):490, doi:10.3390/coatings10050490 (IF -2.881/2020, Q2 – **autor corespondent**) <https://www.mdpi.com/2079-6412/10/5/490>
11. Dumitrascu PA; Stecoza CG; Gavrilescu M; Alecsandrescu C; Ivancencu A; **Anuta V**; Popa L; Ghica MV; Dinu-Pirvu CE. The impact of the lubrication step with magnesium stearate on the quality target product profile of a modified release oral dosage form containing a BCS class II active pharmaceutical ingredient. *Farmacia*, 2020, 68(3), 526-531, doi:10.31925/farmacia.2020.3.19 (IF -1.433/2020, Q4 – **autor corespondent**) https://farmaciajournal.com/wp-content/uploads/2020-03-art-19-Dumitrascu_Dinu-Pirvu_526-531.pdf
12. Dumitrascu PA; Funieru C; **Anuta V**; Coman AG; Alecsandrescu C; Ivancencu A; Popa L; Ghica MV; Dinu-Pirvu CE. Evaluation of the impact of the inlet air humidity during coating step on the in vitro dissolution of modified-release film-coated pellets containing a BCS class I active substance. *Farmacia*, 2020, 68(5), 856-863, doi:10.31925/farmacia.2020.5.12 (IF - 1.433/2020, Q4 – **autor corespondent**) https://farmaciajournal.com/wp-content/uploads/2020-05-art-12-Dumitrascu_Anuta_Dinu-Pirvu_856-863.pdf
13. Mircioiu C, Voicu V, **Anuta V**, Tudose A, Celia C, Paolino D, Fresta M, Sandulovici R, Mircioiu I. Mathematical Modeling of Release Kinetics from Supramolecular Drug Delivery Systems. *Pharmaceutics*, 2019; 11(3): 140, doi: 10.3390/pharmaceutics11030140 (IF - 4.421/2019, Q1, **Highly Cited Paper** – **autor corespondent**) <https://www.mdpi.com/1999-4923/11/3/140>
14. Mircioiu I; **Anuta V**; Mircioiu C; Voicu V; Sandulovici R. Estimation of the effects of food on the pharmacokinetic results in bioequivalence studies. *Revista de Chimie* 2019, 70, 2805-2810 (IF -1.755/2019, Q3 – **autor corespondent**) <https://revistadechimie.ro/Articles.asp?ID=7432>
15. Fierascu RC, Dinu-Pirvu CE, Fierascu I, Tarmure V, Stanica N, Nicolae CA, Somoghi R, Trica B, **Anuta V**. Inorganic/organic core-shell magnetic materials for removal of endocrine disrupting pharmaceuticals from water. *Farmacia*, 2018; 66(2): 316-322 (IF – 1.527/2018, Q4 – **ultim autor**) https://farmaciajournal.com/wp-content/uploads/2018-02-art-18-Fierascu_Fierascu_Anuta_316-322.pdf
16. Fierascu RC, Georgiev MI, Fierascu I, Ungureanu C, Avramescu SM, Ortan A, Georgescu MI, Sutan AN, Zandirescu A, Dinu-Pirvu CE, **Anuta V**. Mitodepressive, antioxidant,



- antifungal and anti-inflammatory effects of wild-growing romanian native *Arctium lappa* L. (*Asteraceae*) and *Veronica persica* Poiret (*Plantaginaceae*). Food and Chemical Toxicology, 2018; 111: 44-52, doi:10.1016/j.fct.2017.11.008 (IF- 3.775/2018, Q1 – ultimul autor) <https://www.sciencedirect.com/science/article/pii/S027869151730666X>
17. Voicu VA, Mircioiu I, Sandulovici R, Mircioiu C, Plesa C, Velescu BS, Anuta V. Chlorpheniramine potentiates the analgesic effect in migraine of usual caffeine, acetaminophen, and acetylsalicylic acid combination. Frontiers in Pharmacology, 2017, 8: 758, doi:10.3389/fphar.2017.00758 (IF- 3.831/2017, Q1 – ultimul autor) <https://www.frontiersin.org/articles/10.3389/fphar.2017.00758/full>
 18. Voicu, V., Mircioiu, C., Anuta, V., Vonica, L.A., and Mircioiu, I., Research concerning the development of a stable, fixed combination of aspirine, paracetamol, caffeine and an antialergic component. Farmacia, 2017; 65(6): 923-928 (IF – 1.507/2017, Q4 - autor corespondent) https://farmaciajournal.com/wp-content/uploads/2017-06-art-16-Voicu_Anuta_Mircioiu_923-928.pdf
 19. Velescu BS, Anuta V, Nitulescu GM, Olaru OT, Ortan A, Ionescu D, Ghica MV, Dragoi CM, Dinu Pirvu, CE. Pharmaceutical assessment of romanian crops of *Anthriscus Sylvestris* (*Apiaceae*). Farmacia, 2017; 65(6): 824-831 (IF – 1.507/2017 Q4 - autor corespondent) https://farmaciajournal.com/arhiva/201706/art-02-Velescu_Anuta_Pirvu_824-831.pdf
 20. Velescu BS, Anuta, V, Aldea, A, Jinga, M, Cobeleschi, PC, Zbarcea, CE, Uivarosi V. Evaluation of protective effects of quercetin and vanadyl sulphate in alloxan induced diabetes model. Farmacia, 2017; 65(2): 200-206 (IF – 1.507/2017, Q4 - autor corespondent) https://farmaciajournal.com/wp-content/uploads/2017-02-art-06-Velescu-et-al.-_200-206.pdf
 21. Savu SN, Silvestro L, Mircioiu C, Anuța V. Development of *In vitro*- *In vivo* Correlation Models for Clopidogrel Tablets to Describe Administration under Fasting and Fed Conditions. Farmacia, 2016; 64(2): 302-312 (IF – 1.348/2016, Q4 – ultimul autor) https://farmaciajournal.com/wp-content/uploads/2016-02-art-25-Simona_Savu_302-312.pdf
 22. Toderescu CD, Dinu-Pîrvu CE, Ghica MV, Anuța V, Popa DE, Vlaia L, Lupuliasa D. Influence of Formulation Variables on Ketoprofen Diffusion Profiles from Hydroalcoholic Gels, Farmacia, 2016, 64(5): 728-735 (IF – 1.348/2016, Q4 - autor corespondent) https://farmaciajournal.com/wp-content/uploads/2016-05-art-13-Dinu_Pirvu_Lupuliasa_728-735.pdf
 23. Burcea Dragomiroiu GTA, Cimpoiesu A, Ginghina O, Baloescu C, Barca M, Popa DE, Ciobanu AM, Anuța V. The Development and Validation of a Rapid HPLC Method for Determination of Piroxicam, Farmacia, 2015; 63(1): 123-31 (IF – 1.162/2015, Q4 – ultimul autor) https://farmaciajournal.com/wp-content/uploads/2015-01-art-20-Burcea_123-131.pdf
 24. Anuța V, Nitulescu GM, Dinu-Pirvu CE, Olaru OT. Biopharmaceutical Profiling of New Antitumor Pyrazole Derivatives. Molecules. 2014; 19(10): 16381-16401, doi:10.3390/molecules191016381 (IF – 2.416/2014, Q2 – prim autor) <https://www.mdpi.com/1420-3049/19/10/16381>
 25. Velescu BS, Anuța V, Uivarosi V. Pharmacokinetic evaluation of a novel ruthenium (III)-ofloxacin complex, as potential therapeutic agent. Farmacia, 2014; 62(5): 1009-1024 (IF – 1.004/2014, Q4 -autor corespondent) https://farmaciajournal.com/wp-content/uploads/2014-05-art-18-Velescu-Uivarosi_1009-1024.pdf
 26. Mircioiu I, Anuța V, Purcaru SO, Radulescu FS, Miron DS, Ibrahim N, Mircioiu C. In vitro dissolution of poorly soluble drugs in presence of surface active agents - in vivo pharmacokinetics correlations. II. Nimesulide. Farmacia, 2013;61(1): 88-102 (IF – 1.251/2013, Q4 – autor corespondent) <https://farmaciajournal.com/wp-content/uploads/2013-01-art-09-2013-1-mircioiu-88-102.pdf>
 27. Uivarosi V, Dinu-Pîrvu CE, Ghica MV, Anuța V. Preformulation studies using cosolvent



- systems to increase the solubility of a new enrofloxacin ruthenium (III) complex with biological activity. *Farmacia*, 2013; 61(1): 127-142 (IF – 1.251/2013, Q4 – ultimul autor) <https://farmaciajournal.com/wp-content/uploads/2013-01-art-12-2013-1-uivarosi-127-142.pdf>
28. Issa AA, Marchidan D, Cojocaru V, Anuța V. Preparation and Evaluation of Meloxicam Solid Dispersion by Melting Method. *Farmacia*, 2013; 61(6): 1216-32, (IF – 1.251/2013, Q4 – ultimul autor) <https://farmaciajournal.com/wp-content/uploads/2013-06-art-18-anmar-1216-1232.pdf>
29. Preda IA, Mircioiu I, Mircioiu C, Corlan G, Pahomi G, Prasacu I, Anuța V. Research concerning the development of a biorelevant dissolution test for formulations containing norfloxacin. I. Modelling of in vitro release kinetics. *Farmacia*, 2012; 60(5): 675-68, (IF – 0.578/2012, Q4 – autor corespondent, ultimul autor) https://farmaciajournal.com/wp-content/uploads/2012-05-art9.preda_.pdf
30. Corlan G, Pahomi G, Sandulovici R, Prasacu I, Ionescu M, Anuța V, Modelling of transfer kinetics of trichlorophon pesticide across cuprophane dialysis membrane in presence and absence of antidote powders, *Farmacia*, 2012;60(6): 915-924 (IF – 0.578/2012, Q4 – autor corespondent, ultimul autor) <http://www.revistafarmacia.ro/201206/art.14.corlan%20915-924.pdf>
31. Pahomi G, Corlan G, Anuța V, Sandulovici RC, Mircioiu I. Study of the influence of bile salts and lecithin on distribution of ketoconazole between plasma and methylene chloride, *Farmacia*, 2012; 60(6): 809-821 (IF – 0.578/2012, Q4 - autor corespondent) <https://farmaciajournal.com/wp-content/uploads/2012-06-art.05.pahomi-809-821.pdf>
32. Mircioiu I, Anuța V, Ibrahim N, Mircioiu C. Dissolution of Tamoxifen in biorelevant media. A two phase release model. *Farmacia* 2012;60(3):315-24, ISSN 0014-8237 (IF – 0.578/2012, Q4 – autor corespondent) <https://farmaciajournal.com/arhiva/201203/art.02.mircioiu%20315-324.pdf>
33. Sandulovici R, Prasacu I, Mircioiu C, Voicu V, Medvedovici A, Anuța V. Mathematical and phenomenological criteria in selection of pharmacokinetic model for M1 metabolite of pentoxifylline. *Farmacia*, 2009; 57(2): 235-246 (IF – 0.144/2009, Q4 – ultimul autor) <https://farmaciajournal.com/arhiva/20092/issue22009art12.pdf>

2. Articole publicate în reviste cotate ISI în calitate de coautor

Criteriul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI în calitate de coautor	5	36

Criteriu îndeplinit: X DA NU

Lista articolelor ISI publicate în calitate de coautor: autori, titlu articol, revistă, an, volum, pagini, factor de impact

- Anghel SA; Dinu-Pirvu CE; Costache MA; Voiculescu AM; Ghica MV; Anuța V; Popa L. Response receptor pharmacogenomics: Deciphering genetic influence on drug, *International Journal of Molecular Sciences*, 2024, 25(17), 9371, doi:10.3390/ijms25179371 (IF – 4.9/2023, Q1) <https://www.mdpi.com/1422-0067/25/17/9371>
- Popescu R; Dinu-Pirvu CE; Ghica MV; Anuta V; Popa L. Physico-chemical characterization and initial evaluation of carboxymethyl chitosan-hyaluronan hydrocolloid systems with



- insulin intended for intranasal administration. *International Journal of Molecular Sciences* 2024, 25, doi:10.3390/ijms251910452 (IF – 4.9/2023, Q1), <https://www.mdpi.com/1422-0067/25/19/10452>
3. Popescu R, Dinu-Pîrvu CE, Ghica MV, Anuța V, Popa L, Development and preliminary evaluation of intranasal hydrocolloidal systems based on chitosan and PVA with insulin, for central nervous system-associated diseases, *Farmacia*, 2024, 72(4), 963-974, doi:10.31925/farmacia.2024.4.25 (IF – 1.4/2023), https://farmaciajournal.com/wp-content/uploads/art-25-Popescu_Popa_Ghica_963-974.pdf
 4. Burloiu AM; Ozon EA; Musuc AM; Anastasescu M; Socoteanu RP; Atkinson I; Culita DC; Anuta V; Popescu IA; Lupuliasa D; Mihai DP; Gird CE; Boscencu R. Porphyrin photosensitizers into polysaccharide-based biopolymer hydrogels for topical photodynamic therapy: Physicochemical and pharmacotechnical assessments. *Gels* 2024, 10, doi:10.3390/gels10080499 (IF – 5/2023, Q1), <https://www.mdpi.com/2310-2861/10/8/499>
 5. Danila E; Kaya DA; Anuta V; Popa L; Coman AE; Chelaru C; Constantinescu RR; Dinu-Pirvu C; Kaya MGA; Ghica MV. Formulation and characterization of niacinamide and collagen emulsion and its investigation as a potential cosmeceutical product. *Cosmetics* 2024, 11, 23, doi:10.3390/cosmetics11020040. (IF – 3.4/2023, Q2) <https://www.mdpi.com/2079-9284/11/2/40>.
 6. Lupuliasa AI; Prisada RM; Matei RI; Avramescu SM; Vasile BS; Fierascu RC; Fierascu I; Voicu-Balasea B; Imre MM; Pituru SM; Anuta V; Dinu-Pîrvu CE. Development of biologically active phytosynthesized silver nanoparticles using *Marrubium vulgare* L. Extracts: Applications and cytotoxicity studies. *Nanomaterials* 2024, 14, 18, doi:10.3390/nano14100895. (IF – 4.4/2023, Q2) <https://www.mdpi.com/2079-4991/14/10/895>
 7. Tudoroiu EE; Dinu-Pirvu CE; Kaya MGA; Popa L; Anuta V; Prisada RM; Ghica MV. An overview of cellulose derivatives-based dressings for wound-healing management. *Pharmaceuticals*, 2021, 14(12): 1215, doi:10.3390/ph14121215 (IF -5.215/2021, Q1) <https://www.mdpi.com/1424-8247/14/12/1215>
 8. Talianu MT; Dinu-Pîrvu CE; Ghica MV; Anuta V; Prisada RM; Popa L. Development and characterization of new miconazole-based microemulsions for buccal delivery by implementing a full factorial design modeling. *Pharmaceutics* 2024, 16, 38, doi:10.3390/pharmaceutics16020271 (IF – 4.9/2023, Q1) <https://www.mdpi.com/1999-4923/16/2/271>
 9. Radu RD; Voicu ME; Prodana M; Demetrescu I; Anuta V; Draganescu D. Electrospun PCL wires loaded with vancomycin on zirconium substrate. *Materials* 2023, 16, 20, doi:10.3390/ma16227237. (IF – 3.1/2023, Q1) <https://www.mdpi.com/1996-1944/16/22/7237>
 10. Tudoroiu EE; Kaya MGA; Titorencu I; Dinu-Pirvu CE; Marin MM; Rosca AM; Popa L; Anuta V; Antoniac A; Chelaru C; Kaya DA; Prisada RM; Ghica MV. Design and evaluation of new wound dressings based on collagen-cellulose derivatives. *Materials and Design* 2023, 236, 17, doi:10.1016/j.matdes.2023.112469. (IF – 7.6/2023, Q1) <https://www.sciencedirect.com/science/article/pii/S0264127523008845>
 11. Voicu ME; Ionita D; Buica GO; Draganescu D; Anuta V; Raduly FM; Demetrescu I. Characterization of two types of polylactic acid coating loaded with gentamicin sulphate deposited on az31 alloy. *Coatings* 2023, 13, 14, doi:10.3390/coatings13061105. (IF – 2.9/2023, Q2) <https://www.mdpi.com/2079-6412/13/6/1105>
 12. Voicu ME; Draganescu D; Anuta V; Stoian AB; Ionita D; Demetrescu I. The interrelationship between the drug embedded tizr surface properties and antibacterial effect. *Farmacia* 2022, 70, 1064-1071, doi:10.31925/farmacia.2022.6.9. (IF – 1.6/2022, Q4)



- https://farmaciajournal.com/wp-content/uploads/art-09-Voicu_Draganescu_Demetrescu_1064-1071-re.pdf
13. Ozon EA; Novac M; Gheorghe D; Musuc AM; Mitu MA; Sarbu I; **Anuta V**; Rusu A; Petrescu S; Atkinson I; Lupuliasa D. Formation and physico-chemical evaluation of nifedipine-hydroxypropyl-beta-cyclodextrin and nifedipine-methyl-beta-cyclodextrin: The development of orodispersible tablets. *Pharmaceutics* 2022, 15, doi:10.3390/ph15080993 (IF – 4.6/2022, Q2) <https://www.mdpi.com/1424-8247/15/8/993>
 14. Anicescu MC; Dinu-Pirvu CE; Talianu MT; Ghica MV; **Anuta V**; Prisada RM; Nicoara AC; Popa L. Insights from a box-behnken optimization study of microemulsions with salicylic acid for acne therapy. *Pharmaceutics*, 2022, 14(1): 174, doi:10.3390/pharmaceutics14010174 (IF -5.4/2022, Q1) <https://www.mdpi.com/1999-4923/14/1/174>
 15. Talianu MT; Dinu-Pirvu CE; Ghica MV; **Anuta V**; Jinga V; Popa L. Foray into concepts of design and evaluation of microemulsions as a modern approach for topical applications in acne pathology. *Nanomaterials* 2020, 10(11): 2292, doi:10.3390/nano10112292 (IF - 5.076/2020, Q1) <https://www.mdpi.com/2079-4991/10/11/2292>
 16. Popescu R; Ghica MV; Dinu-Pirvu CE; **Anuta V**; Lupuliasa D; Popa L. New opportunity to formulate intranasal vaccines and drug delivery systems based on chitosan. *International Journal of Molecular Sciences*, 2020, 21(14):5016, doi:10.3390/ijms21145016 (IF - 5.924/2020, Q1) <https://www.mdpi.com/1422-0067/21/14/5016>
 17. Sandulovici R; Aboul-Enein HY; Voice V; Ghafil AF; Mati E; **Anuta V**; Sarbu I; Mircioiu I. Determination and modelling of in vitro release kinetics of mebendazole in simulated intestinal fluid from solid dispersion formulations as infinite reservoirs. *Acta Polonica Pharmaceutica* 2020, 77, 849-861, doi:10.32383/appdr/131112 (IF -0.330/2020, Q4) https://www.ptfarm.pl/download/?file=File%2FActa_Polonica%2F2020%2F6%2F849.pdf
 18. Musuc AM; **Anuta V**; Atkinson I; Popa VT; Sarbu I; Mircioiu C; Abdalrb GA; Mitu MA; Ozon EA. Development and characterization of orally disintegrating tablets containing a captopril-cyclodextrin complex. *Pharmaceutics*, 2020, 12(8):744, doi:10.3390/pharmaceutics12080744 (IF -6.321/2020, Q1) <https://www.mdpi.com/1999-4923/12/8/744>
 19. Voicu VA, Mircioiu C, Plesa C, Jinga M, Balaban V, Sandulovici R, Costache AM, **Anuta V**, Mircioiu I. Effect of a New Synergistic Combination of Low Doses of Acetylsalicylic Acid, Caffeine, Acetaminophen, and Chlorpheniramine in Acute Low Back Pain. *Frontiers in Pharmacology*, 2019; 10: 607, doi: 10.3389/fphar.2019.00607 (IF -4.225/2019, Q1 - **toti autorii au avut contribuție egală**) <https://www.frontiersin.org/articles/10.3389/fphar.2019.00607/full>
 20. Mircioiu C; **Anuta V**; Mircioiu I; Nicolescu A; Fotaki N. In vitro-in vivo correlations based on in vitro dissolution of parent drug diltiazem and pharmacokinetics of its metabolite. *Pharmaceutics*, 2019, 11(7): 344, doi:10.3390/pharmaceutics11070344 (IF -4.421/2019, Q1) <https://www.mdpi.com/1999-4923/11/7/344>
 21. Fierascu I; Fierascu IC; Dinu-Pirvu CE; Fierascu RC; **Anuta V**; Velescu BS; Jinga M; Jinga V. A short overview of recent developments on antimicrobial coatings based on phytosynthesized metal nanoparticles. *Coatings* 2019, 9(12), doi:10.3390/coatings9120787 (IF -2.436/2019, Q2) <https://www.mdpi.com/2079-6412/9/12/787/htm>
 22. Olaru OT, Zanfirescu A, Nitulescu GM, Nitulescu G, Dinu-Pirvu CE, **Anuta V**, Tsatsakis A, Spandidos DA, Margina D, Seremet OC. Predictive power of the *Triticum* root elongation test for the assessment of novel anti-proliferative therapies. *International Journal of Molecular Medicine*, 2019; 44(1): 16-24, doi: 10.3892/ijmm.2019.4192 (IF -3.098/2019, Q3) <https://www.spandidos-publications.com/10.3892/ijmm.2019.4192>
 23. Fierascu RC, Fierascu I, Ortan A, Fierascu IC, **Anuta V**, Velescu BS, Pituru SM, Dinu-Pirvu



- CE. *Leonurus cardiaca* L. as a Source of Bioactive Compounds: An Update of the European Medicines Agency Assessment Report (2010). *Biomed Research International*, 2019; vol 2019, Article ID 4303215, 13 pages, doi: 10.1155/2019/4303215, 2019 (IF -2.276/2019, Q3) <https://www.hindawi.com/journals/bmri/2019/4303215/cta/>
24. Irimia T; Musat GC; Prisada RM; Ghica MV; Dinu-Pirvu CE; Anuta V; Velescu BS; Popa L. Contributions on formulation and preliminary evaluation of ocular colloidal systems of chitosan and poloxamer 407 with bupivacaine hydrochloride. *Farmacia* 2019, 67(4), 702-708, doi:10.31925/farmacia.2019.4.20 (IF -1.607/2019, Q4) https://farmaciajournal.com/wp-content/uploads/2019-04-art-20-Irimia_Musat_Popa_702-708.pdf
25. Ancuceanu, R., Dinu, M., Dinu-Pirvu, C., Anuta, V., Negulescu, V. Pharmacokinetics of B-Ring Unsubstituted Flavones. *Pharmaceutics*, 2019, 11(8): 370, doi: 10.3390/pharmaceutics11080370 (IF - 4.421/2019, Q1) <https://www.mdpi.com/1999-4923/11/8/370>
26. Fierascu I, Dinu-Pirvu CE, Fierascu RC, Velescu BS, Anuta V, Ortan A, Jinga V. Phytochemical profile and biological activities of *Satureja hortensis* L.: A review of the last decade. *Molecules*, 2018; 23(10): 2458, doi:10.3390/molecules23102458 (IF -3.06/2018, Q2) <https://www.mdpi.com/1420-3049/23/10/2458>
27. Irimia T, Ghica MV, Popa L, Anuța V, Arsene AL, Dinu-Pîrvu CE. Strategies for improving ocular drug bioavailability and corneal wound healing with chitosan-based delivery systems. *Polymers*, 2018; 10(11): 1221, doi:10.3390/polym10111221 (IF -3.164/2018, Q1) <https://www.mdpi.com/2073-4360/10/11/1221>
28. Marin MM, Albu Kaya MG, Ignat M, Ghica MV, Dinu-Pîrvu CE, Anuța V, Popa L. Collagen-lidocaine microcapsules with controlled release for tooth extraction pain. *Revista de Chimie*, 2018; 69(5): 1213-1215 (IF - 1.605/2018) http://www.revistadechimie.ro/article_eng.asp?ID=6291
29. Fierascu I, Ungureanu C, Avramescu SM, Cimpeanu C, Georgescu MI, Fierascu RC, Ortan A, Sutan AN, Anuta V, Zanfirescu A, Dinu-Pirvu CE, Velescu BS. Genoprotective, antioxidant, antifungal and anti-inflammatory evaluation of hydroalcoholic extract of wild-growing *Juniperus communis* L. (*Cupressaceae*) native to romanian southern sub-carpathian hills. *BMC Complementary and Alternative Medicine*, 2018; 18(1): 3, doi:10.1186/s12906-017-2066-8 (IF- 2.479/2018, Q2) <https://bmccomplementaltermmed.biomedcentral.com/articles/10.1186/s12906-017-2066-8>
30. Tuchilă C, Baconi D, Anuța V, Dinu-Pîrvu CE, Vlăsceanu AM, Bălălău C, Constantin MM, Stan M. Development of a high performance chromatographic method for therapeutic drug monitoring of carbamazepine based on an experimental design approach. *Farmacia*, 2018; 66(3): 452-462 (IF - 1.507/2017, Q4 - toti autorii au avut contribuție egală) https://farmaciajournal.com/wp-content/uploads/2018-03-art-09-Tuchila_Baconi_Stan_452-462.pdf
31. Ailiesei, I, Anuta, V, Mircioiu, C, Cojocar, V, Orbesteanu, AM, and Cinteza, LO, Application of Statistical Design of Experiments for the Optimization of Clodronate Loaded Liposomes for Oral Administration, *Revista de Chimie*, 2016, 67(8): 1566-1570, (IF - 1.232/2016, Q4) <http://bch.ro/pdfRC/AILIESEI%208%2016.pdf>
32. Gherghiceanu F, Sandulovici R, Prasacu I, Anuta V, Mircioiu C. Bioequivalence Implies Therapeutic Equivalence. I. Biostatistical Approach, *Farmacia*, 2016; 64(6): 823-827 (IF - 1.348/2016, Q4) https://farmaciajournal.com/wp-content/uploads/2016-06-art-03-Gherghiceanu_823-827.pdf
33. Prasacu I, Mircioiu C, Anuța V, Radulescu F, Sandulovici R, Lupuleasa D, Atkinson J, Rombaut B, Rais C, Belu I. PHAR-QA quality assurance - Erasmus project: II. Gauging effectiveness of quality assurance activities in PHAR-QA "Kick-Off" meeting. *Farmacia*,



- 2014; 62(4): 642-648 (IF – 1.004/2014, Q4) <https://farmaciajournal.com/wp-content/uploads/2014-04-art-02-Prasacu-642-648.pdf>
34. Rais C, Anuța V, Rădulescu FS, Prasacu I, Lupuleasa D, Atkinson J, Rombaut B, Mircioiu C. Quality Assurance PHAR-QA - Erasmus Project I. Contribution of "Carol Davila" University of Medicine and Pharmacy Bucharest. Farmacia, 2014; 62(2): 236-244, (IF – 1.004/2014, Q4) https://farmaciajournal.com/wp-content/uploads/2014-02-art-01-Rais_Cristina-236-244.pdf
35. Marchidanu D, Raducanu N, Miron DS, Radulescu FS, Anuța V, Mircioiu I, Prasacu I. Comparative Pharmacokinetics Of Rifampicin And 25-Desacetyl Rifampicin In Healthy Volunteers After Single Oral Dose Administration. Farmacia, 2013;61(2): 398-410 (IF – 1.251/2013, Q4) <https://farmaciajournal.com/wp-content/uploads/2013-02-art-18-marchidanu-398-410.pdf>
36. Ranetti MC, Ionescu M, Hinescu L, Ionică E, Anuța V, Ranetti AE, Stecoza CE, Mircioiu C. Validation of a HPLC method for the simultaneous analysis of metformin and gliclazide in human plasma. Farmacia, 2009; 57(6): 728-735 (IF – 0.144/2009) <https://farmaciajournal.com/arhiva/20096/issue62009art07.pdf>

3. Factorul cumulat de impact pentru articolele publicate ca autor principal în reviste cotate ISI (FCIAP)

Criteriul	Standard minim	Realizat
(ISI) Factor cumulat de impact autor principal	10	82.562

Criteriu îndeplinit: DA NU

4. Indexul Hirsch

Criteriul	Standard minim	Realizat
Index Hirsch	6	16

Criteriu îndeplinit: DA NU

Note asupra metodei de calcul:

1. O revistă cotate ISI este o revistă pentru care Thomson Reuters calculează și publică factorul de impact în „Journal Citation Reports”;
2. Autorul sau autorii principali ai unei publicații se consideră a fi oricare dintre următorii:
 - a. Primul autor
 - b. Autorul corespondent
 - c. Alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent
 - d. Ultimul autor



UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE „CAROL DAVILA“ DIN BUCUREȘTI



Str. Dionisie Lupu 37, sector 2, București, 020021, România, www.umfcd.ro, email: rectorat@umfcd.ro

3. În analiză vor fi incluse articole originale și reviews. În cazul publicațiilor în reviste cu factor de impact mai mare decât 3, pot fi luate în considerare și alte tipuri de publicații in extenso (nu rezumate).
4. Articolele din cadrul standardelor minimale și obligatorii trebuie să fie **publicate și indexate**, nu în curs de publicare (nu se acceptă adeverințe).
5. Factorul cumulat de impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP). FCIAP = suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI; **factorul de impact este cel din anul publicării articolului.**
6. Va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science, Core Collection, Thomson Reuters, pentru întreaga carieră a candidatului („all years”);

Confirm prin prezenta că datele menționate mai sus sunt reale și se referă la propria mea activitate profesională și științifică

Data

15.09.2024

Semnătura candidatului,